The Use of the Immune Epitope Database to Study Autoimmune Epitope Data Related to Alopecia Areata  by Sette, Alessandro et al.
The Use of the Immune Epitope Database to Study
Autoimmune Epitope Data Related to Alopecia Areata
Alessandro Sette1, Sinu Paul1, Kerrie Vaughan1 and Bjoern Peters1
The Immune Epitope Database (IEDB) is a repository of
published epitope data for infectious diseases, allergy,
transplantation and autoimmunity. Herein we provide
an introduction to the IEDB search interface, focusing
on data related to autoimmune diseases, including
alopecia areata (AA). We demonstrate how common
questions related can be answered, such as how to
search for specific autoantigens, epitope sequences,
response types (B- and/or T-cell assays), or host, as well
as how to search for epitopes of known major histo-
compatibility complex restriction and for data related
to a specific disease. Our survey of the data found that
while as a whole Autoimmunity-specific records
represent a significant portion (B30%); epitopes
reported for AA are remarkably few, just 23 epitopes
from six antigens. This reveals a significant knowledge
gap for AA, and suggests that additional mapping of
epitopes and identification of novel AA-associated
autoantigens is warranted. Citing recently published
examples, we show how bioinformatic, proteomic, and
technological advances make it now increasingly
feasible to identify epitopes and novel antigens in
human disease. The goal herein was to increase aware-
ness of the IEDB as a free resource for the scientific
community and to demonstrate its use in finding
(existing) and analyzing (prediction) epitope data.
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INTRODUCTION
The Immune Epitope Database and Analysis Resource (IEDB;
IEDB.org) is an NIAID sponsored freely available resource that
serves as a warehouse of published antibody and T-cell
epitope data (Vita et al., 2015). As of March 2015, it hosts
4128,000 different sequences and structures, and nearly
800,000 curated experimental assays. As we will briefly
discuss below, the IEDB’s design allows for highly granular
searches including, for example, the epitope structure, the
epitope’s derivative antigen (or autoantigen), host, disease
associations, antibody, and/or T-cell assays of interest,
references, as well as numerous other potential criteria.
The scope of the IEDB includes four broad disease
categories: infectious disease; allergy; autoimmunity; and
transplantation. In addition to the database as an epitope
repository, the IEDB also houses a number of analysis tools
with capability as diverse as epitope prediction, three-dimen-
sional visualization, and population coverage. It is important
to point out that the IEDB does not generate experimental
data; it simply captures published epitope data and provides
tools to predict and analyze epitopes.
THE IEDB ALLOWS FLEXIBLE QUERIES TO RETRIEVE
EXPERIMENTAL DATA
The design of the database and associated query strategies
allow the user to search the data using six main areas. These
include, epitope, antigen, assay, major histocompatibility
complex (MHC) restriction, host and disease. Figure 1
provides a screen shot of the IEDB’s main search interface
(IEDB.org) showing these six main ‘‘search panes.’’ From each
main search pane the user can enter or select criteria for their
query of interest. For example, in the epitope pane, the user
can specify the nature of the epitope (linear, discontinuous, or
non-peptidic), its sequence, whether to search for exact or
homologous sequences, and so on. In the Antigen pane, one
can enter a protein name or alternatively, search by its
derivative organism. This can include pathogens (virus, bac-
teria), allergens, or even self, as would be the case with
autoantigens. The antigen-specific search can be focused on a
specific protein or set of proteins, specified by using a single
branch on our protein tree menu.
The assay pane can be used to limit the search to specific
‘‘assay types’’. This is accomplished by selecting the response
type of interest at the high level: T-cell assays, B-cell assays, or
MHC ligand assays. Similarly, the MHC restriction and host
panes allow the user to limit or specify search parameters
related to MHC restriction as defined in the assay, and/or to
specify a particular host, whether human or animal model.
Lastly the disease pane allows the user to choose among the
four main categories of disease, infectious, allergy, autoim-
mune (AI), and transplant-related, referring to the clinical
manifestation of the host.
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Once the initial query criteria are selected and the user hits
‘‘search,’’ a results page will be generated. The results page is
organized with a central tab delineated summary table, as
well as access to additional detailed search panes along left-
hand side (Figure 2). On the Results table there are four tabs:
(i) epitopes, (ii) antigens, (iii) assays, and (iv) references. Each
tab shows in parentheses the total number of records from the
latest query and can be clicked open to reveal data details (by
row or column). Clicking on rows within a tab allows access
to all details of the experiments captured within. Figure 3
show an example of the assays tab opened to show data
content and organization. If the user chooses, the search can
then be changed or further refined using the search panes
along the left-hand side, specifying any number of additional
parameters. Clicking the green ‘‘search’’ button updates the
current query parameters and results. Search refinements
performed at this level can include any field in the database.
Current and pending search criteria ‘‘filters’’ are tracked along
the top of the results page for quick reference.
SEARCHING THE IEDB FOR ALOPECIA RELATED DATA
REVEALS A SIGNIFICANT GAP IN KNOWLEDGE
To specifically query for AI related records, the user can
simply select on the home page from the disease pane,
‘‘autoimmune disease.’’ This search will return more than
10,000 epitopes that are associated with AI disease. Here, the
results page tabs show: epitopes (9,741); antigens (1,951);
assays (22,350); and references (2,465). As indicated above,
the user can change or further refine this broad query using the
specific search panes provided along the left side of this page.
For example, the search may be limited to retrieve only
human AI data specific, whereby the total is now 6,993
epitopes (data not shown).
In another example, the user might choose to restrict the
search to a specific AI, such as diabetes mellitus (type I
diabetes; T1D). This can be accomplished by scrolling down
to the left-hand disease pane, clicking on specific disease and
then typing ‘‘diabetes mellitus’’ into the free-text field. T1D is
a good example, as it is a highly-studied AI disease and
Figure 1. Immune Epitope Database (IEDB) Search Interface. A screen shot showing the main search interface on IEDB.org. The interface is comprised of six main
‘‘search panes,’’ epitope, antigen, assay, major histocompatibility complex (MHC) restriction, host and disease, which allow the user to select specific criteria
pertaining to the nature of the epitope(s) of interest (e.g., linear T-cell epitopes from protein X) or to limit their query to certain subsets of the cumulative data (e.g.,
particular host with disease).
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therefore provides a useful ‘‘ruler’’ for comparison to AA.
Here, we find nearly 2,000 diabetes-related epitopes (1,887 in
total) are described from 964 different antigens and reported
from 261 references (screen shot not shown).
Repeating the same search using ‘‘alopecia areata’’ (AA)
and ‘‘alopecia’’ (both terms exist in the data) reveals by
comparison a substantial paucity of experimental data.
Indeed, only 23 epitopes derived from six antigens are
retrieved from the search. Antigens reported thus far for AA
include tyrosine hydroxylase, keratins type I and II, melano-
cyte protein PMEL (gp100), melan A (MART-1), and melano-
cortin 1 receptor (MC1R). This result was somewhat
surprising, not only due to the low number of identified
epitopes and associated antigens but also because of the
potential relationship of AA with proteins heretofore consider
solely as cancer antigens. This suggests that there may be
potential for additional relevant data associated with melano-
cyte cancer antigens that are not currently curated by the
IEDB, since cancer is not within its programmatic scope.
Using the IEDB curation process we estimate that as many as
500 papers in PubMed potentially contain information related
to epitopes from melanocyte antigens.
In conclusion, the IEDB represents a potential resource that
could aid in the study of AA as the database is designed to
enable easy yet highly granular queries of the AI epitope data.
Indeed, a specific search of existing data for ‘‘alopecia areata’’
revealed a scant 23 T- and B-cell epitopes, thus highlighting
a substantial knowledge gap. Many of the AA-associated
epitopes reported to date are derived from well-known cancer
antigens, and while additional as yet uncurated papers have
been identified in PubMed, it does not seem likely that this
data gap could be remedied by curating these additional
references. Thus, further defining of AA-related epitope reper-
toires (determinants, as well as antigens) in humans, as well as
in animal models of disease, is warranted.
THE USE OF THE IEDB ANALYSIS RESOURCE TO
PREDICT POTENTIAL EPITOPES
In addition to the extensive database, the IEDB web page can
be used to predict potential epitopes. This strategy is particu-
larly applicable in cases, like AA, where existing knowledge is
limited. The IEDB Analysis Resource (Figure 4a) provides
numerous bioinformatics tools which allow for the prediction
of B- and T-cell epitopes, including proteolytic processing, as
well as various other epitope analysis tools that enable the
user to calculate population coverage or the degree of
conservation of epitope(s) within a set of protein sequences
of interest.
A user may be interested in predicting T-cell epitopes for a
given autoantigen (e.g., tyrosine hydroxylase), using a specific
disease-associated subset of HLA class II alleles, such as
HLA-DQB1*03:03 and DRB1*0401, which have been asso-
ciated with AA (Hordinsky and Ericson, 2004). The IEDB class
II prediction tool (Figure 4b.) takes the antigen sequence of
interest (accession or copy/paste) and selected alleles (one or
more), and then readily generates a list of potential candidate
Figure 2. Results summary page for ‘‘alopecia areata’’ query. The Results page is generated from any query initiated on the Immune Epitope Database (IEDB)
home page. Query results are presented on a tab delineated table located centrally on this page. On the Results table there are four tabs: (i) epitopes, (ii) antigens,
(iii) assays, and (iv) references. Each tab shows in parentheses the total number of records from the latest query and can be clicked open to reveal data details (by
row or column). Clicking on rows within a tab allows access to all details of the experiments captured within. If the user wishes to change or refine an ongoing
query, search panes located along the left-hand side on this page are provided. Queries performed on this page are nearly limitless, as access to all database fields
is provided.
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peptides sorted by likelihood of binding (in IC50 (nM) or by
percentile rank) that can be tested in the laboratory.
In conclusion, in additional to the experimentally derived
data housed within the IEDB, analysis tools such as epitope
prediction algorithms can be used to identify potential
candidate peptides that can be subsequently analyzed in the
laboratory. It is important to note that, in the case of AA,
presumably not all relevant autoantigens have been identified,
thus the applicability of this approach is currently limited to
the six reported autoantigens, tyrosine hydroxylase, keratin
types I and II, melanocyte protein PMEL (gp100), melan A
(MART-1), and MC1R.
TECHNOLOGY IS AVAILABLE TO GENERATE TARGETED
EXPERIMENTAL DATA
Recent years have witnessed significant advances in the
ability of investigators to accurately identify and characterize
the antigen and epitopes associated with disease.
Technological advancement now allows for high throughput
antigen and epitope identification. These approaches
rely on combination of bioinformatics, proteomics, next-
generation sequencing and high-capacity assays. Indeed,
NIAD has employed such technologies through contracts
tackling biodefense targets, emerging and reemerging
diseases, as we as allergens. As a result, this field is
moving past anecdotal evidence, into population-based
studies.
For example, Lindestam Arlehamn et al. (2013) have
screened pools of predicted HLA class II binders
corresponding to over 4,000 open reading frames (ORFs)
encoded in the genome of Mycobacterium tuberculosis (TB).
As a result, hundreds of new epitopes and antigens recognized
in the TB-specific disease process were discovered. This study
demonstrated the technical feasibility of simultaneously
screening and identifying thousands of pathogen-associated
ORFs recognized by humans with clinical disease.
In a different study (Weiskopf et al., 2013), characterized
dengue virus (DENV)-specific CD8þ HLA class I-restricted
T-cell responses in hundreds of individuals from hyper-
endemic areas. This resulted in the first high-resolution map
of T-cell responses in the general population of an endemic
area (Sri Lanka). In this study, which included more than 700
patients, a total of 408 epitopes were described, 80% of which
were novel. Moreover, this work established that CD8þ
T-cells are associated with protection from disease caused
by DENV. As above, this study demonstrates the feasibility of
screening a large population of subjects with disease for
specific T-cell responses (CD8þ ). It further shows that large-
scale epitope identification can facilitate the identification of
correlates of protection.
Finally, Schulten et al. (2013) have recently demonstrated
that proteomic approaches could be utilized to identify novel
allergens. In that study, two-dimensional (2D) gel analysis was
utilized to separate grass pollen extracts. Individual spots
Figure 3. Results page assay tab opened showing the content and organization of data by columns and rows. Here, the assay tab of the results table has been
clicked open to reveal the overall content and organization of the assay-specific data. Note the smaller tabs present at the top summarize data for all response
types, T-cell assays, B-cell assays, and major histocompatibility complex (MHC) ligand assays (if present/reported) with the totals shown in parentheses. Below, the
data are organized into nine columns: assay ID, reference, epitope, host, immunization, assay antigen, antigen epitope relation, MHC restriction and assay
description, providing a quick snap shot of the individual records. Clicking on any row will allow the user to ‘‘drill down’’ into each record to see details of the
experimental process and outcome. The entire set of T-cell assays shown in this query (as an example) could be downloaded in Excel by clicking the Excel
(Microsoft, Redmond, WA) icon in the top right corner.
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selected based on antibody or protein staining, were cut out
from the gels and analyzed by mass spectrometry. As a result,
83 new proteins from 2D gelþ10 proteins from whole extract
mass spectrometry were chosen for further studies. These data
were then used to perform T-cell antigen identification based
on HLA class II binding predictions. A total of 822 peptides
predicted to bind a panel of 25 common HLA class II
molecules (DR, DP, DQ) were subsequently tested for IL-5
production using peripheral blood (peripheral blood
mononuclear cells) from allergic donors. The results clearly
indicated that the majority of T helper 2 cells in allergic
donors target these novel epitopes. The results from these
three studies exemplify the feasibility of large-scale epitope
and antigen identification studies in humans with disease.
CONCLUSIONS AND OUTLOOK: A NEW APPROACH
FOR ALOPECIA AREATA
In summary, the IEDB resource could aid in the study of AA.
Herein we have provided several examples demonstrating the
general use of the database to search for AI epitope data.
However, our survey of the existing data reveals a substantial
knowledge gap with respect to AA, as only 23 epitope have
been defined thus far from six antigens. Moreover, most of
these represent melanocyte-associated antigens. Although
Figure 4. The Immune Epitope Database (IEDB) analysis resource. The IEDB analysis resource is an integrated part of the epitope database and provides T-cell
epitope prediction, B-cell epitope prediction, as well as other epitope analysis tools, including population coverage, conservation across antigens, clusters with
similar sequences, location in three-dimensional (3D) structure. (a) The analysis resource menu located on the right side of the IEDB home page. (b) The T-cell
prediction tool menu opened to highlight available methods.
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additional papers of potentially relevance may be found in the
existing literature (PubMed), filling the gap identified herein
will require the generation of additional experimental data
going forward. The IEDB analysis resource could be used to
predict epitopes, as this is particularly applicable in cases
where existing epitope repertoires are limited. However, this
approach requires that at least some, if not many, of the
relevant antigens associated with the pathology are estab-
lished. Once established, these antigens can be used in
prediction analyses to generate sets of potential class I or II
specific epitopes for subsequent testing in humans.
As highlighted above, large-scale studies published in the
past few years demonstrate that these methods and new
technologies are available to generate targeted experimental
data. We suggest that proteomic analysis could be applied to
AA to map a subset of several hundred candidate proteins
expressed specifically at the site of pathology, the human hair
follicle. The IEDB class I and class II T-cell prediction tools can
be used to generate specific sets of peptides to screening in AA
patients. In this context, it will be critical to count on the
availability of patient samples in the form of peripheral blood
donations, perhaps partnering with existing patient advocate
groups and resources. Ultimately, we believe that it should be
possible to extend the technology already successfully applied
to infectious diseases and allergies to autoimmunity as well,
and AA in particular. A broader definition of the autoantigens
associated with AA pathology seems now to be a feasible task,
which could be realized in the not too distant future.
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